Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity
- PMID: 25908323
- PMCID: PMC4550087
- DOI: 10.1016/j.drugalcdep.2015.03.032
Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity
Abstract
Background: Severe alcoholism can be associated with significant nutritional and vitamin deficiency, especially vitamin B1 (thiamine) which is associated with neurological deficits impacting mood and cognition. Alcohol consumption was reduced among female but not male alcoholics after supplementation with the high potency thiamine analog benfotiamine (BF). We examined the relationship between lifetime alcoholism severity, psychiatric symptoms and response to BF among the alcohol dependent men from this cohort.
Methods: Eighty-five adult men (mean age=48±8 years) meeting DSM-IV-TR criteria for a current alcohol use disorder who were abstinent <30days participated in a randomized, double-blind, placebo-controlled trial of 600mg BF vs placebo (PL) for 6 months. Psychometric testing included a derived Lifetime Alcoholism Severity Score (AS), Symptom Checklist 90R (SCL-90R), and the Barratt Impulsivity Scale (BIS) at baseline and at 6 months.
Results: Baseline SCL-90-R scale scores for men with high alcoholism severity (AS≥24; N=46 HAS) were significantly greater than for men with low alcoholism severity (AS<24; N=39 LAS), but BIS scores did not differ. MANOVA modeling at follow-up (N=50 completed subjects) identified a significant treatment effect (F=2.5, df=10, p<0.03) and treatment×alcoholism severity level interaction (F=2.5, dfnum=10, dfden=30, p<0.03) indicating reduced SCL-90-R scores among BF treated, HAS males. Above normal plasma thiamine levels at follow-up predicted reduced depression scores in a BF-treated subset (F=3.2, p<0.09, N=26).
Conclusion: BF appears to reduce psychiatric distress and may facilitate recovery in severely affected males with a lifetime alcohol use disorder and should be considered for adjuvant therapy in alcohol rehabilitation.
Trial registration: #NCT00680121 High Dose Vitamin B1 to Reduce Abusive Alcohol Use.
Keywords: Alcoholism; Benfotiamine (BF); Thiamine deficiency; Vitamin B1.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statement
No conflict declared
Figures




Similar articles
-
Multiplex Immunoassay of Plasma Cytokine Levels in Men with Alcoholism and the Relationship to Psychiatric Assessments.Int J Mol Sci. 2016 Mar 29;17(4):472. doi: 10.3390/ijms17040472. Int J Mol Sci. 2016. PMID: 27043532 Free PMC article.
-
Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence.Drug Alcohol Depend. 2013 Dec 1;133(2):562-70. doi: 10.1016/j.drugalcdep.2013.07.035. Epub 2013 Aug 11. Drug Alcohol Depend. 2013. PMID: 23992649 Free PMC article. Clinical Trial.
-
Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial.Eur Arch Psychiatry Clin Neurosci. 2016 Dec;266(8):695-702. doi: 10.1007/s00406-016-0685-6. Epub 2016 Mar 16. Eur Arch Psychiatry Clin Neurosci. 2016. PMID: 26984349 Clinical Trial.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Therapeutic potential of vitamin B1 derivative benfotiamine from diabetes to COVID-19.Future Med Chem. 2022 Jun;14(11):809-826. doi: 10.4155/fmc-2022-0040. Epub 2022 May 10. Future Med Chem. 2022. PMID: 35535731 Review.
Cited by
-
High-dose thiamine strategy in Wernicke-Korsakoff syndrome and related thiamine deficiency conditions associated with alcohol use disorder.Indian J Psychiatry. 2021 Mar-Apr;63(2):121-126. doi: 10.4103/psychiatry.IndianJPsychiatry_440_20. Epub 2021 Apr 14. Indian J Psychiatry. 2021. PMID: 34194054 Free PMC article. Review.
-
Multiplex Immunoassay of Plasma Cytokine Levels in Men with Alcoholism and the Relationship to Psychiatric Assessments.Int J Mol Sci. 2016 Mar 29;17(4):472. doi: 10.3390/ijms17040472. Int J Mol Sci. 2016. PMID: 27043532 Free PMC article.
-
Baclofen for alcohol use disorder.Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD012557. doi: 10.1002/14651858.CD012557.pub3. Cochrane Database Syst Rev. 2023. PMID: 36637087 Free PMC article. Review.
References
-
- Abou-Saleh MT, Coppen A. The biology of folate in depression: implications for nutritional hypotheses of the psychoses. J Psychiatr Res. 1986;20:91–101. - PubMed
-
- Abou-Saleh MT, Coppen A. Folic acid and the treatment of depression. J Psychosom Res. 2006;61:285–287. - PubMed
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. APA; Washington DC: 2000. pp. 1–943. text revision.
-
- . Benfotiamine. Altern Med Rev. 2006;11:238–242. - PubMed
-
- Ayazpoor U. Chronic alcohol abuse. Benfotiamine in alcohol damage is a must. MMW Fortschr Med. 2001;143:53. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous